A randomized controlled study of effectiveness of labetalol versus hydralazine in the management of severe pre-eclampsia in Ahmadu Bello university teaching hospital, Zaria.
Phase 3
Recruiting
- Conditions
- Preeclampsia
- Registration Number
- PACTR202408671139802
- Lead Sponsor
- Sakina Ghazali
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
1.Severe hypertension (systolic blood pressure of 160mmHg or more and /or diastolic blood pressure of 110mmHg or more) and Proteinuria of 2+ or more as measured by dipstick in a catheter specimen urine sample.
2.Pregnancy = 28 weeks gestation.
3.Singleton pregnancy.
4.Live fetus with normal fetal heart rate.
Exclusion Criteria
1.Medicaldisorderslikeasthma,cardiacfailure,heartblock, cardiac arrhythmias.
2.Contraindication or known allergy to hydralazine or labetalol neurological disease.
3.Fetal congenital abnormality.
4.Women who refuse consent.
5.Referrals already on anti-hypertensive.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome <br>Number of doses/ total dosage, unit drop in systolic blood pressure and diastolic blood pressure after each administered dose, time to achieve target of blood pressure which is systolic blood pressure of 140–150 mmHg and diastolic blood pressure of 90–100 mmHg as end point of effectiveness and non-attainment of target blood pressure after stipulated maximum dosage.
- Secondary Outcome Measures
Name Time Method 1 Persistent severe hypertension and requirement of additional drug to control blood pressure.<br>2 Medication-related undesirable effects on both mother and baby.<br>